Biogen Q4 revenue $2.4B, GAAP EPS $1.71; 2024 Non-GAAP EPS guidance $15-$16

BIOGEN INC.

2023-FY EPS reported $7.97 revenue$9,835,600,000

Q4 2023 revenue $2.4B (-6% YoY); GAAP EPS $1.71 vs $3.79; Non-GAAP EPS $2.95 vs $4.05
Full year 2023 revenue $9.8B (-3% YoY); GAAP EPS $7.97 vs $20.87; Non-GAAP EPS $14.72 vs $17.67
EPS negatively impacted by $0.35 from ADUHELM closeout costs; LEQEMBI co-promotion announced
2024 guidance: Non-GAAP EPS $15.00-$16.00 (~5% growth vs 2023); revenue expected down low- to mid-single digit
SKYCLARYS launched with ~1,000 patients; ZURZUVAE postpartum depression launch; 'Fit for Growth' $1B gross savings by 2025

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOGEN INC. reported fourth quarter 2023 results: revenue $2.4 billion, EPS GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95.

Period: fourth quarter 2023
Revenue: $2.4 billion
EPS: GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95
Result: reported results

Exact text from the filing

Fourth quarter 2023 revenue $2.4 billion; GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOGEN INC. reported full year 2024 results: revenue total revenue to decline by a low- to mid-single digit percentage vs. 2023, EPS Non-GAAP EPS of $15.00 to $16.00. Guidance initiated.

Period: full year 2024
Revenue: total revenue to decline by a low- to mid-single digit percentage vs. 2023
EPS: Non-GAAP EPS of $15.00 to $16.00
Guidance: initiated
Result: guidance update

Exact text from the filing

Full year 2024 financial guidance: Non-GAAP EPS of $15.00 to $16.00, representing EPS growth of approximately 5% versus 2023 at the mid-point • Expect total revenue to decline by a low- to mid-single digit percentage vs. 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOGEN INC. reported full year 2023 results: revenue $9.8 billion, EPS GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72.

Period: full year 2023
Revenue: $9.8 billion
EPS: GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72
Result: reported results

Exact text from the filing

Full year 2023 revenue $9.8 billion; GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72

View on SEC.gov

Browse all earnings releases →

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0000875045-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.